E
Eugene Braunwald
Researcher at Brigham and Women's Hospital
Publications - 1758
Citations - 278949
Eugene Braunwald is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Myocardial infarction & TIMI. The author has an hindex of 230, co-authored 1711 publications receiving 264576 citations. Previous affiliations of Eugene Braunwald include Boston University & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Implications for acute intervention related to time of hospital arrival in acute myocardial infarction
Zoltan G. Turi,Peter Stone,James E. Muller,Corette B. Parker,Robert E. Rude,Daniel E. Raabe,Allan S. Jaffe,Tyler Hartwell,Thomas L. Robertson,Eugene Braunwald +9 more
TL;DR: The time from onset of symptoms to arrival in the hospital emergency room (ER) was studied in 778 patients randomized into a study of acute myocardial infarction (AMI) size limitation, and a significantly higher mortality rate was observed in patients who arrived late.
Journal ArticleDOI
Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction.
Erin A. Bohula,Marc P. Bonaca,Eugene Braunwald,Philip E. Aylward,Ramón Corbalán,Gaetano M. De Ferrari,Ping He,Basil S. Lewis,Piera Angelica Merlini,Sabina A. Murphy,Marc S. Sabatine,Benjamin M. Scirica,David A. Morrow +12 more
TL;DR: Stratification of baseline atherothrombotic risk can assist with therapeutic decision making for vorapaxar use for secondary prevention after MI and net clinical outcome was increasingly favorable with vorAPaxar across risk groups.
Journal ArticleDOI
Evaluation of Multiple Biomarkers of Cardiovascular Stress for Risk Prediction and Guiding Medical Therapy in Patients With Stable Coronary Disease
Marc S. Sabatine,David A. Morrow,James A. de Lemos,Torbjørn Omland,Sarah Sloan,Petr Jarolim,Scott D. Solomon,Marc A. Pfeffer,Eugene Braunwald +8 more
TL;DR: Elevated levels of novel biomarkers of cardiovascular stress may help identify patients who are at higher risk of cardiovascular death and heart failure and may be useful to select patients who derive significant benefit from angiotensin-converting enzyme inhibitor therapy.
Journal ArticleDOI
The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure.
TL;DR: A molecular complex, LCZ696, developed by scientists at Novartis, combines an angiotensin receptor blocker with a neprilysin inhibitor, is well tolerated, and represents an important step in the management of heart failure and reduced ejection fraction.
Journal ArticleDOI
Association of elevated B-type natriuretic peptide levels with angiographic findings among patients with unstable angina and non-ST-segment elevation myocardial infarction.
Saihari Sadanandan,Saihari Sadanandan,Christopher P. Cannon,Kasi Chekuri,Sabina A. Murphy,Peter M. DiBattiste,David A. Morrow,James A. de Lemos,Eugene Braunwald,C. Michael Gibson +9 more
TL;DR: Among patients with UA/NSTEMI, elevated BNP levels are associated with tighter culprit stenosis, higher CTFC, and LAD involvement, and may partly explain the association between Elevated BNP and adverse outcomes.